The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EBMT 2025 | Key challenges in the treatment of patients with PTCL
In this video, Gandhi Damaj, MD, PhD, University of Caen Normandie Hospital Center, Caen, France, briefly outlines the key challenges in treating patients with peripheral T-cell lymphoma (PTCL), highlighting that patients with relapsed/refractory (R/R) disease should be bridged to allogeneic stem cell transplantation (alloSCT) promptly. This interview took place at the 51st Annual Meeting of the EBMT in Florence, Italy.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, there are too many key challenges because we don’t have enough treatment to put patients in sensitive disease in complete remission, because we are all aware that patients who are in complete remission fare better than patients who are in stable disease or in progressive disease. Complete remission or partial remission will have the same result after allo for the major entities...
Yeah, there are too many key challenges because we don’t have enough treatment to put patients in sensitive disease in complete remission, because we are all aware that patients who are in complete remission fare better than patients who are in stable disease or in progressive disease. Complete remission or partial remission will have the same result after allo for the major entities. Okay? That’s a major problem with PTCL, and when they relapse, putting them in chemo-sensitive disease is very hard. And the most important point for those patients who are in the relapsed setting or who are refractory to the first-line treatment is not to forget that whatever the treatment we choose is to put the patient on the track for allo. That’s why we need to search for a donor as soon as possible and when we have chemosensitive disease to go to transplant.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Research Grant from Takeda.
